RIGL: Summary for Rigel Pharmaceuticals, Inc. - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, November 25, 2009, 2:46pm EST - Canadian Markets close in 1 hour and 14 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Rigel Pharmaceuticals, Inc. (RIGL)

At 14:30 EST: 8.06 USD

0.06 (0.75%)

MORE ON RIGL

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Rigel Pharmaceuticals, Inc. (NGM:RIGL) Delayed quote data

Last Trade:	8.06 USD
Trade Time:	2:30PM EST
Change:	0.06 (0.75%)
Prev Close:	8.00
Open:	8.03
Bid:	8.06 x 500
Ask:	8.07 x 500
1y Target Est:	15.70

Day's Range:	7.97 - 8.10
52wk Range:	4.19 - 14.75
Volume:	303,464
Avg Vol (3m):	818,665
Market Cap:	417.68M
P/E (ttm):	N/A
EPS (ttm):	-3.24
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y max

Add RIGL to Portfolio

Download Data

HEADLINES

•	Rigel shares rise on RBC analyst upgrade
	AP (Mon, Nov 23)

•	Rigel Pharms upgraded by RBC Capital Mkts
	Briefing.com (Mon, Nov 23)

•	Piper Jaffray Award Winning Analyst Says Health Care Reform Equity Valuation Fears Have Passed: Stock Picks For Q4 2009
	Wall Street Transcript (Tue, Nov 10)

•	Bristol Licenses Arthritis Drug: BioBuzz
	at TheStreet.com (Tue, Nov 10)

•	Biosimilars, Biologics, Biotech And Specialty Pharmaceuticals: Piper Jaffray Picks The Stocks And Sectors With Highest Potential Returns For Investors
	Wall Street Transcript (Fri, Nov 6)

•	RIGEL PHARMACEUTICALS INC Financials
	EDGAR Online Financials (Fri, Nov 6)

•	New Star Analyst Rankings for Rigel Pharmaceuticals, Inc.
	StarMine (Wed, Nov 4)

•	RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
	EDGAR Online (Tue, Nov 3)

•	Rigel reports $26.7M loss in Q3
	at bizjournals.com (Tue, Nov 3)

•	UPDATE - Rigel to move arthritis drug forward; posts weak Q3
	at Reuters (Tue, Nov 3)

More Headlines for RIGL...

ANALYST

EPS Est (next year) (Dec-09) :	-2.72
EPS Est (in 2 years) (Dec-10) :	-1.35
Avg Rec (current)*:	1.8
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Rigel Pharmaceuticals, Inc., a clinical-stage drug development company, engages in the discovery and development of novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and cancer, as well as viral and metabolic diseases.

Full Company Profile

Add to Portfolio

Email to a Friend

•